Healthcare
Aureos takes 33% stake in Philippines hospital
The Aureos South-East Asia Fund has invested $4 million in the Batangas-based Daniel O. Mercado Medical Center (DMMC), for a 33% stake.
Actis exits 63% stake in India's Paras for 10x return
Actis, the London-headquartered emerging markets investment firm, will sell its 63% stake in Paras Pharmaceuticals Limited to Benckiser Group, a UK-based company selling household, health and personal care products.
Healthcare Locums confirms purchase of CHAMP PE investee Healthcare Australia
UK-based Healthcare Locums has confirmed its acquisition of Healthcare Australia Holdings Pty, which is majority-owned by CHAMP Private Equity, via the payment of A$122.5 million ($118.6 million) in cash.
Taiwan Development Fund invests in Taiwan Medtech
Taiwan’s National Development Fund has made its maiden allocation under its so-called ‘Diamond Action Plan for Biotech Takeoff’ by deploying $80 million to the Taiwan Medtech fund, according to its announcement.
Infinity makes latest push in Tianjin with life science fund, accelerator
In its latest move, Infinity Group, the Israel-originated PRC-focused investor, has announced a new life sciences fund and business accelerator platform in Tianjin, collectively accounting for RMB220 million ($33 million).
ICICI Venture sells RFCL to PE-backed Avantor Performance Materials
ICICI Venture has sold its 85% stake in Indian biotech firm RFCL to PE-backed chemical developer Avantor Performance Materials.
MSPE Sihuan Pharma IPO looks to strong healthcare exit
Morgan Stanley Private Equity investee Sihuan Pharmaceutical is on track to raise $741 million, potentially rising to $850 million if a greenshoe option is exercised, after pricing its IPO high at 26.7x next year's earnings, in the world's second largest...
Matrix Partners hands $11.3 million to Centre for Sight
Matrix Partners has invested INR50 crore ($11.3 million) in New Delhi-based eyecare specialist Centre for Sight, enabling the hospital chain to expand its operations across India via acquisitions and the launch of new facilities.
Symphony-backed Zenith Pharmaceuticals exits nine-year investee Strides Arcolab
Zenith Pharmaceuticals, the majority-owned asset of Symphony Capital, is nearing the completion of its exit from Indian pharmaceutical firm Strides Arcolab, with reports that Zenith is poised to see 5.7x returns on its nine-year investment.
Singapore's Bio*One, Adams Street, others, invest US medical device company TriReme
TriReme Medical Inc., which develops catheters and stents for treating vascular disease, has raised $17 million in Series D financing led by new Singaporean investor Bio*One Capital, as well as return investors Three Arch Partners and global private equity...
IFCI Venture Capital to partially exit Marck Biosciences
IFCI Venture Capital is selling a nearly 10% stake in Indian pharma firm Marck Biosciences, according to local reports, coming as the investee looks to build an INR55 crore ($12.4 million) manufacturing plant.
Sequoia India invested $16 million in biopharmaceutical play Celon Labs
Sequoia Capital India has invested INR70 crore ($16 million) in Celon Labs, a Hyderabad-based biopharmaceutical company with established brands in oncology, critical care and gynaecology.
Crescent sells National Hearing Care to international buyer
Crescent Capital Partners and Macquarie Group have sold local hearing healthcare business National Hearing Care Group (NHC) to Italian hearing aid retailer Amplifon SA, the leading global player in the sector, for A$460 million ($441 million).
J-STAR drives healthcare in Japan
In a deal that displays PE's ability to drive sector change in Japan, and that highlights the continuing buoyancy of the local mid-market, J-STAR Co., Ltd. has bought out Apo Plus Station Co. Ltd., a privately-held medical solutions company, in an MBO....
TPG PRC investee ShangPharma targets listing on NYSE
ShangPharma Corp., a PRC company offering R&D outsourcing services for the pharma and biotech markets, and invested by TPG Capital, has filed for an IPO on the NYSE.
CHAMP seeks sale exit for Healthcare Australia
CHAMP Private Equity is in discussions with at least three potential buyers, both strategic players and other PE firms, about a potential sale of its nursing and aged care staffing business Healthcare Australia, with a probable price tag of around A$150...
Crescent Capital sells NHC for $441 million
Australian PE firm Crescent Capital has sold its hearing healthcare firm National Hearing Care Group (NHC) to Italian hearing aid retailer Amplifon SA for A$460 million ($441 million), choosing to make its exit via a strategic sale instead of taking a...
Aureos exits 34% stake in Indian pharma research firm Accutest
Aureos Capital has fully exited its 34% stake in Indian clinical research group Accutest Research Laboratories to investment firm Greater Pacific Capital Ltd. for an undisclosed amount.
ICICI, PE-backed Arch Pharmalabs gets $14.3 million from Mitsui
Japanese trading firm Mitsui has taken a 5% stake in PE-backed Indian pharmaceutical producer Arch Pharmalabs for some INR65 crore ($14.3 million), coming ahead of Arch’s planned IPO early next year.
TPG set to make $69 million through Parkway Life exit
TPG Capital is reportedly looking to offload its 9.3% stake in Singapore-based healthcare REIT Parkway Life, via a sale that could fetch as much as S$91.1 million ($69 million).
Sabre Capital-backed Spring Healthcare to invest in Indian hospital groups
Sabre Capital-owned Spring Healthcare is reportedly set to infuse approximately INR100 crore ($21.6 million) in two Indian hospital groups in Tier Two cities, which could potentially give it as much as 40% in each group.
Taisho, others assessing Actis, Sequoia India investee Paras Pharma
Japanese pharma major Taisho Pharmaceutical Co. Ltd., as well as at least one other leading non-Indian drug firm, is conducting due diligence on Actis Capital and Sequoia Capital investee Paras Pharmaceuticals, in a competitive exit process that could...
Australia's Crescent Capital plans National Hearing healthcare IPO
Crescent Capital Partners, a mid-market Australian private equity firm, is planning an IPO for investee National Hearing Care, an audiology business, possibly as early as October.
Acumen India director Sahni quits for healthcare with Global Impact
Varun Sahni, formerly India Director with US-headquartered international social venture fund Acumen, is now launching his own private equity vehicle, Global Impact Investors (GII), targeting to raise $100 million, with a focus on services in emerging...